Medical AI Alliance
Company Index
Pharma & CDMOKOSDAQ 000250304 approvals26 trials

SAM CHUN DANG PHARM CO. LTD

Official website

Founded 1943, KOSDAQ-listed 2000, Sam Chun Dang Pharm makes Hameron and Atorrow, with contrast-agent and biosimilar license deals.

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Sam Chun Dang Pharm was founded in 1943 and listed on KOSDAQ in 2000, with subsidiaries Optus Pharm, SCD US, SCD BIOTECH, and SCD JAPAN. It built a KGMP plant in the Hyangnam complex, Hwaseong in 1985, making prescription drugs such as antibiotics, cardiovascular/digestive treatments, and ophthalmic products including Hameron and Atorrow. Consolidated revenue rose 9.9% YoY to KRW 231.8 billion, with operating profit KRW 8.5 billion and net income KRW 11.6 billion; it holds a USD 5,000,000 license-in deal with SUMMIT BIOTECH for contrast agents and a USD 42,700,000 exclusive Japan supply deal with Senju Pharmaceutical for an Aflibercept biosimilar.

Products & technology

  • 하메론
  • 아토로우

Regulatory approvals

data.go.kr

304 Korean MFDS drug approvals · 1987–2026

  • MFDS drugS-Tego Tab. 50mg2026-07-20
    Drug · Prescription · Approval202602079
  • MFDS drugS-Tego Tab. 25mg2026-07-20
    Drug · Prescription · Approval202602080
  • MFDS drugDobian Tab. 500mg (Dobesilate Calcium hydrate)2026-06-26
    Drug · Prescription · Approval202601822
  • MFDS drugS-napine eye drops0.05%(Epinastine Hydrochloride)(Single dose)2026-05-19
    Drug · Prescription · Approval202601452
  • MFDS drugGlifensupreme Plus Tab.2025-12-15
    Drug · Prescription · Approval202503282
  • MFDS drugMucopro SR Tab. 150mg2025-10-15
    Drug · Prescription · Approval202502663
  • MFDS drugVgenfli Injection (Aflibercept)2025-09-22
    Drug · Prescription · Approval202502500
  • MFDS drugVgenfli Pre-filled Syringe (Aflibercept)2025-09-22
    Drug · Prescription · Approval202502501
  • MFDS drugLatast Eye Drops (Latanprost)2024-12-20
    Drug · Prescription · Approval202403035
  • MFDS drugCircuromin Tab. 240mg(Ginkgo Leaf Dried ext.)2024-10-31
    Drug · OTC · Notification202402575
  • MFDS drugGluliptin duo XR Tab. 5/1000mg(Linagliptin,Metformin Hydrochloride)2024-03-26
    Drug · Prescription · Approval202400662
  • MFDS drugGluliptin duo XR Tab. 2.5/1000mg(Linagliptin,Metformin Hydrochloride)2024-03-26
    Drug · Prescription · Approval202400663
Show 68 more
  • MFDS drugMonte Q Plus Tab. 10/5mg2023-10-30
    Drug · Prescription · Approval202303016
  • MFDS drugRostel plus tab. 80/5/5mg2023-09-25
    Drug · Prescription · Approval202302814
  • MFDS drugRostel plus tab. 40/5/5mg2023-09-25
    Drug · Prescription · Approval202302815
  • MFDS drugEmforga Duo Tab. 12.5/1000mg2023-09-20
    Drug · Prescription · Approval202302783
  • MFDS drugEmforga Duo Tab. 12.5/850mg2023-09-20
    Drug · Prescription · Approval202302784
  • MFDS drugEmforga Duo Tab. 12.5/500mg2023-09-20
    Drug · Prescription · Approval202302785
  • MFDS drugRostel plus tab. 40/5/10mg2023-06-29
    Drug · Prescription · Approval202302007
  • MFDS drugRostel plus tab. 80/5/10mg2023-06-29
    Drug · Prescription · Approval202302008
  • MFDS drugJanuglu Tab. 50mg2023-06-27
    Drug · Prescription · Approval202301961
  • MFDS drugJanuglu Tab. 100mg2023-06-27
    Drug · Prescription · Approval202301962
  • MFDS drugS-forga Duo XR Tab. 10/500mg2023-06-21
    Drug · Prescription · Approval202301903
  • MFDS drugJanuglu M Tab. 50/500mg2023-06-12
    Drug · Prescription · Approval202301797
  • MFDS drugJanuglu M Tab. 50/1000mg2023-06-12
    Drug · Prescription · Approval202301798
  • MFDS drugJanuglu M Tab. 50/850mg2023-06-12
    Drug · Prescription · Approval202301799
  • MFDS drugMirtel Tab. 20mg2023-05-02
    Drug · Prescription · Approval202301422
  • MFDS drugRosutin Tab. 2.5mg2023-04-14
    Drug · Prescription · Approval202301248
  • MFDS drugJanuglu M XR Tab. 50/500mg2023-02-17
    Drug · Prescription · Approval202300593
  • MFDS drugJanuglu M XR Tab. 50/1000mg2023-02-17
    Drug · Prescription · Approval202300594
  • MFDS drugJanuglu M XR Tab. 100/1000mg2023-02-17
    Drug · Prescription · Approval202300595
  • MFDS drugDaforgaduo XR Tab. 10/500mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)2023-01-12
    Drug · Prescription · Approval202300227
  • MFDS drugDaforgaduo XR Tab. 10/1000mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)2023-01-12
    Drug · Prescription · Approval202300228
  • MFDS drugS-forga Duo XR Tab. 10/100mg2023-01-06
    Drug · Prescription · Approval202300153
  • MFDS drugDaforga Tab. 10mg (Dapagliflozin Propanediol Monohydrate)2023-01-03
    Drug · Prescription · Approval202300026
  • MFDS drugEmforga Duo Tab. 5/1000mg2022-04-04
    Drug · Prescription · Approval202201363
  • MFDS drugEmforga Duo Tab. 5/850mg2022-04-04
    Drug · Prescription · Approval202201364
  • MFDS drugEmforga Duo Tab. 5/500mg2022-04-04
    Drug · Prescription · Approval202201365
  • MFDS drugTelia M SR Tab. 10/500mg2022-04-04
    Drug · Prescription · Approval202201432
  • MFDS drugTelia M SR Tab. 20/1000mg2022-04-04
    Drug · Prescription · Approval202201433
  • MFDS drugTelia M SR Tab. 10/750mg2022-04-04
    Drug · Prescription · Approval202201434
  • MFDS drugDr-clear eye drops 1.0%(Carboxymethylcellulose Sodium)(Single dose)2022-03-24
    Drug · OTC · Notification202201194
  • MFDS drugDaforga plus tab. 10/100mg2022-01-04
    Drug · Prescription · Approval202200050
  • MFDS drugPointamin Plus 500/1000 Tab.2021-10-28
    Drug · OTC · Notification202107174
  • MFDS drugPointamin Plus 300/1000 Tab.2021-10-28
    Drug · OTC · Notification202107175
  • MFDS drugPointamin Plus 100/1000 Tab.2021-10-28
    Drug · OTC · Notification202107176
  • MFDS drugAmlovan Plus Tab. 5/80/5mg2021-08-27
    Drug · Prescription · Approval202106218
  • MFDS drugAmlovan Plus Tab. 5/80/10mg2021-08-27
    Drug · Prescription · Approval202106219
  • MFDS drugAmlovan Plus Tab. 5/160/5mg2021-08-27
    Drug · Prescription · Approval202106220
  • MFDS drugAmlovan Plus Tab. 5/160/10mg2021-08-27
    Drug · Prescription · Approval202106221
  • MFDS drugLeprozin CR tab. (Levodropropizine)2021-06-30
    Drug · Prescription · Approval202104978
  • MFDS drugNexzole Duo Tab. 20/800mg2021-06-18
    Drug · Prescription · Approval202104751
  • MFDS drugEmforga Tab. 25mg (Empagliflozin)2021-03-05
    Drug · Prescription · Approval202102076
  • MFDS drugEmforga Tab. 10mg (Empagliflozin)2021-03-05
    Drug · Prescription · Approval202102077
  • MFDS drugAtolow Plus Tab. 10/10mg2021-01-08
    Drug · Prescription · Approval202100215
  • MFDS drugAtolow Plus Tab. 10/20mg2021-01-08
    Drug · Prescription · Approval202100216
  • MFDS drugAtolow Plus Tab. 10/40mgRevoked2021-01-08
    Drug · Prescription · Approval202100217
  • MFDS drugS-tonib tab. 5mg (Tofacitinib Aspartate)Revoked2021-01-07
    Drug · Prescription · Approval202100140
  • MFDS drugTelia tab. 20mg (Teneligliptin Hydrochloride Hydrate)2020-11-05
    Drug · Prescription · Approval202007622
  • MFDS drugIrisplus Eye Drops (Single dose), Irisplus Eye Drops2020-07-21
    Drug · OTC · Notification202005205
  • MFDS drugS-forga Tab. 10mg (Dapagliflozin)Revoked2020-06-17
    Drug · Prescription · Approval202004453
  • MFDS drugMopuren SR Tab. 15mg (Mosapride Citrate Hydrate)2020-04-24
    Drug · Prescription · Approval202002988
  • MFDS drugCircuromin Tab. 80mg (Ginkgo Leaf Dried ext.)2020-04-22
    Drug · OTC · Notification202002841
  • MFDS drugOloten-high 0.7% Eye Drops(Olopatadine Hydrochloride), Oloten-high 0.7% Eye Drops(Olopatadine Hydrochloride)(Single dose)2020-04-20
    Drug · Prescription · Approval202002757
  • MFDS drugGluliptin duo Tab. 2.5/1000mgRevoked2020-03-25
    Drug · Prescription · Approval202002090
  • MFDS drugGluliptin duo Tab. 2.5/850mgRevoked2020-03-25
    Drug · Prescription · Approval202002091
  • MFDS drugGluliptin duo Tab. 2.5/500mgRevoked2020-03-24
    Drug · Prescription · Approval202002038
  • MFDS drugLevosta Eye Drops1.5%(Levofloxacin Hydrate)2020-02-27
    Drug · Prescription · Approval202001383
  • MFDS drugCasfun Inj. 70mg (Caspofungin Acetate)2020-02-27
    Drug · Prescription · Approval202001388
  • MFDS drugCasfun Inj. 50mg (Caspofungin Acetate)2020-02-27
    Drug · Prescription · Approval202001389
  • MFDS drugFaster Tab. 20mg (Famotidine)2020-01-29
    Drug · Prescription · Approval202000476
  • MFDS drugCombimonin Eye Drops (Single dose)Revoked2019-11-22
    Drug · Prescription · Notification201908049
  • MFDS drugMonteQ Gran. 4mg (Montelukast Sodium)2019-11-15
    Drug · Prescription · Approval201907953
  • MFDS drugMerotase Enteric Coated Tab. (Bromelain)2019-10-29
    Drug · OTC · Notification201907548
  • MFDS drugMonteQ chewable Tab. 4mg (Montelukast Sodium)2019-10-22
    Drug · Prescription · Approval201907401
  • MFDS drugMonteQ chewable Tab. 5mg (Montelukast Sodium)2019-10-22
    Drug · Prescription · Approval201907405
  • MFDS drugBaronac Eye drops(Bromfenac Sodium Hydrate)2019-10-18
    Drug · Prescription · Notification201907353
  • MFDS drugKerorol Nail Lacquer2019-08-13
    Drug · OTC · Notification201905687
  • MFDS drugDiquaron Eye drops(Diquafosol sodium), Diquaron Eye drops(Diquafosol sodium)(Single dose)2019-08-07
    Drug · Prescription · Approval201905586
  • MFDS drugForten Eye drops(Prednisolone Acetate)2019-07-23
    Drug · Prescription · Notification201905235

Showing the 80 most recent of 304 records.

Clinical trials

data.go.kr

26 MFDS clinical trial authorisations · 2012–2024 (Bioequivalence 20 · Phase 1 4 · Phase 3 2)

  • Bioequivalence에스보노정20밀리그램(보노프라잔푸마르산염)2024-12-20

    1 trial site

  • Phase 3타로스트점안액(YDS-2101)2024-09-05

    25 trial sites

  • Bioequivalence쎄티린정(레보세티리진염산염)2024-04-23

    2 trial sites

  • Bioequivalence에스캡정50밀리그램(테고프라잔)2023-05-01

    1 trial site

  • Bioequivalence도비안정500밀리그램(도베실산칼슘수화물)2023-02-07

    2 trial sites

  • Bioequivalence다포가정10밀리그램(다파글리플로진프로판디올수화물)2021-11-02

    1 trial site

  • Bioequivalence미르텔정80밀리그램(텔미사르탄)2021-04-20

    1 trial site

  • Bioequivalence자누글루정100밀리그램(시타글립틴인산염)2021-04-16

    1 trial site

  • Bioequivalence넥트라캡슐40mg2020-12-22

    1 trial site

  • Bioequivalence타리에스비정(베포타스틴베실산염)2020-10-22

    1 trial site

  • Phase 3SCD4112020-09-02

    52 trial sites

  • Bioequivalence엠포가듀오정5/1000밀리그램2020-02-19

    1 trial site

Show 14 more
  • Bioequivalence엠포가정25밀리그램(엠파글리플로진)2019-12-04

    1 trial site

  • Phase 1다포가정10밀리그램(다파글리플로진)2018-10-05

    1 trial site

  • Bioequivalence벤라팩트서방캡슐(벤라팍신염산염)2017-07-12

    2 trial sites

  • Bioequivalence글루젠타정(리나글립틴)2016-10-05

    2 trial sites

  • Bioequivalence노비코정2016-09-22

    2 trial sites

  • Phase 1SCD212-1, SCD212-22016-05-18

    1 trial site

  • Bioequivalence레토스정(클래리트로마이신)2014-02-19
  • Bioequivalence투세프정(세프프로질)2013-12-20
  • Bioequivalence도비안정(도베실레이트칼슘)2013-09-27

    2 trial sites

  • Bioequivalence넥스졸캡슐40mg(에스오메프라졸마그네슘)2013-06-05

    1 trial site

  • Bioequivalence지텐션정5밀리그램(에스암로디핀베실산염)2013-03-19

    1 trial site

  • Bioequivalence로수틴정20mg2013-02-01

    1 trial site

  • Phase 1디엠피메트엑스알정15/500밀리그램2012-03-23

    1 trial site

  • Phase 1디엠피메트엑스알정15/500밀리그램2012-03-23

    1 trial site

R&D and key agreements

Source: DART corporate disclosure

조영제 2품목 라이센스인 (SCD501, SCD502) · MRI 조영제(양성자 T1/T2 이완시간 측정을 통한 조직·혈관 영상 조영) · SCD502: PV batch 제조 예정 / SCD501: 제형개발(처방연구) · License-in agreement for 2 contrast agent products (Gadovist, Dotarem) from SUMMIT BIOTECH International Co., Ltd, signed 2018-07-26, total contract value USD 5,000,000

AI reads

MAA server logs · IP-verified
0
Read to answer a question

Someone asked an AI a question, and it fetched this page live to answer.

2
Crawled for indexing

Collected for later use. Not a signal of interest.

0answer
index 2
Last 7 days
0answer
index 2
Last 30 days
0answer
index 2
All time
  • OpenAIOAI-SearchBot2

Measured since Aug 26, 2026 · 1 AI engines · last read Aug 26, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS.

Connect this index to your AI tool →

Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryPharma & CDMO

IL DONG PHARMACEUTICAL CO., LTD.100

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

Yuyu Pharma, Inc.100

Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.

ILDONG HOLDINGS CO.,LTD100

Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.

Medy-Tox Inc.99

Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.

GC Biopharma Corp.97

KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.

BIO-FD&C CO.,LTD.85

Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.

DAEWON PHARMACEUTICAL CO.,LTD85

KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.

SAMSUNG BIOLOGICS CO.,LTD.85

Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.

GENOLUTION INC.85

Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.

HANDOK Inc.85

KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.

HL GENOMICS Co., Ltd.85
Kolmar BioTech, Inc.85

Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.

Sources and updates

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
AI visibility
Measured 2026-08-13

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition